DK0655247T3 - Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau - Google Patents

Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Info

Publication number
DK0655247T3
DK0655247T3 DK94403014T DK94403014T DK0655247T3 DK 0655247 T3 DK0655247 T3 DK 0655247T3 DK 94403014 T DK94403014 T DK 94403014T DK 94403014 T DK94403014 T DK 94403014T DK 0655247 T3 DK0655247 T3 DK 0655247T3
Authority
DK
Denmark
Prior art keywords
substances
vincristine
determination
level
neural level
Prior art date
Application number
DK94403014T
Other languages
Danish (da)
English (en)
Inventor
Francois-Xavier Coude
Umberto Guzzi
Jacqueline Fournier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0655247T3 publication Critical patent/DK0655247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK94403014T 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau DK0655247T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
DK0655247T3 true DK0655247T3 (da) 2002-02-18

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme

Country Status (17)

Country Link
US (3) US5229389A (ko)
EP (2) EP0655247B1 (ko)
JP (2) JP2618115B2 (ko)
KR (1) KR0181330B1 (ko)
AT (2) ATE207747T1 (ko)
BR (1) BR9105015A (ko)
CA (2) CA2042974C (ko)
CY (1) CY2283B1 (ko)
DE (2) DE69115989T2 (ko)
DK (2) DK0458696T3 (ko)
FR (1) FR2662355B1 (ko)
HK (1) HK1001471A1 (ko)
HU (1) HU208922B (ko)
IE (1) IE911707A1 (ko)
IL (3) IL112167A (ko)
TW (1) TW216771B (ko)
ZA (1) ZA913865B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
NZ320355A (en) * 1995-10-26 2000-03-27 Sanofi Sa Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
CA2042974C (en) 2002-09-17
US5229389A (en) 1993-07-20
FR2662355B1 (fr) 1994-11-10
IL98175A0 (en) 1992-06-21
EP0655247A1 (fr) 1995-05-31
DK0458696T3 (da) 1996-05-20
DE69132797T2 (de) 2002-05-29
CA2365832C (en) 2007-08-07
KR0181330B1 (ko) 1999-03-20
HU911729D0 (en) 1991-12-30
CA2042974A1 (en) 1991-11-22
IL112167A (en) 1996-01-31
BR9105015A (pt) 1993-05-25
IE20011078A1 (en) 2002-03-20
ATE207747T1 (de) 2001-11-15
EP0458696A2 (fr) 1991-11-27
IE911707A1 (en) 1991-12-04
HK1001471A1 (en) 1998-06-19
AU7713391A (en) 1991-11-28
CA2365832A1 (en) 1991-11-23
EP0458696A3 (en) 1992-03-18
JP2954029B2 (ja) 1999-09-27
DE69132797D1 (de) 2001-12-06
EP0458696B1 (fr) 1996-01-03
CY2283B1 (en) 2003-07-04
EP0655247B1 (fr) 2001-10-31
IL98175A (en) 1996-01-19
TW216771B (ko) 1993-12-01
JP2618115B2 (ja) 1997-06-11
DE69115989D1 (de) 1996-02-15
JPH04226917A (ja) 1992-08-17
DE69115989T2 (de) 1996-08-22
US5468753A (en) 1995-11-21
AU636488B2 (en) 1993-04-29
ZA913865B (en) 1992-02-26
ATE132369T1 (de) 1996-01-15
IL112167A0 (en) 1995-03-15
HUT59824A (en) 1992-07-28
JPH09132535A (ja) 1997-05-20
US5270320A (en) 1993-12-14
KR910019617A (ko) 1991-12-19
FR2662355A1 (fr) 1991-11-29
HU208922B (en) 1994-02-28

Similar Documents

Publication Publication Date Title
DK0655247T3 (da) Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau
DE3177156D1 (de) Guanin-verbindungen und ihre verwendung zur herstellung eines antivirusmittels.
DE69100547D1 (de) Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen.
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE59003423D1 (de) Vorrichtung zum Injizieren von Flüssigkeiten.
DE69006905D1 (de) Analysator mit kreisförmiger, auf einen Inkubator zentrierter Kassettenbahn und Verfahren zu seiner Verwendung.
DE58903504D1 (de) Verfahren zur messung der konzentration optisch aktiver substanzen und anordnung zur durchfuehrung des verfahrens.
Rickson et al. Social bases of farmers' responses to land degradation.
DE59009364D1 (de) Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums.
IT8122181A0 (it) Metodo ed apparecchio per rivelare sostanze emettitrici di particelle alfa.
AT383491B (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
DE3860590D1 (de) Verfahren und vorrichtung zum kontinuierlichen gewinnen von organischen polymerisaten aus ihren loesungen oder emulsionen.
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE69107203D1 (de) Wirbelbettverfahren zum imprägnieren von fasern mit polymer-pulvern und vorrichtung dafür.
ATE9343T1 (de) 2,6-diethyl-3,5-dimethyl-2,3-dihydro-4h-pyran, verfahren zu seiner herstellung und seine verwendung zur frueherkennung, lokalisierung und bekaempfung von lasioderma serricorne f.
DE69103425D1 (de) Verfahren zur verhinderung der zerstörung von meerwasserzellen durch biologische verschmutzung.
Manning River Recreation Use and Analysis of Carrying Capacity
PT66268A (de) N-methyl-n-(toluolsulfonsaeuremethylamid-n'-sulfenyl)-2,2-dimethyl-2,3-dihydrobenzofuranyl-(7)-carbamat,verfahren zu seiner herstellung und seine insektizide verwendung
DE59103597D1 (de) Verfahren zum ermitteln der kraftstoffeinspritzmenge.
McFarland Behavioural transitions: A reply to Roper and Crossland.
Adamek et al. The biological value of chub(Leuciscus cephalus), roach(Rutilus rutilus), and perch(Perca fluviatilis) at two different habitats of the Dalesice Reservoir(Czechoslovakia).
EHLER et al. Water quality guidance: Development of residuals management strategies. An executive summary[Socioeconomic Environmental Studies Series]
DE68918599D1 (de) Verfahren zur bestimmung der biologischen aktivität eines bodens.
Sherwood Effects on marine life: fin erosion disease induced in the laboratory.
ATE78480T1 (de) Purin- und pyrimidin-verbindungen und deren verwendung als antivirusmittel.